UTS (U2AF1/TP53/SRSF2) high-risk mutation signature in SMF
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.: Large MYSEC-cohort NGS study formalizes UTS (U2AF1/TP53/SRSF2) as a high-risk mutation signature in post-PV/post-ET MF, contributing (alongside ASXL1 and optional complex/monosomal karyotype) to the refined MYSEC-mPM and MYSEC-kmPM scores that outperform clinical MYSEC-PM for overall-survival prediction. (novelty: 3)
Open questions
Related
Contributing findings
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
01-jul-2026
novelty 3
per-area 3
introduces